Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Dec 21;14(1):33.
doi: 10.3390/ani14010033.

Successful Emergency Management of a Dog with Ventilator-Dependent Acquired Myasthenia Gravis with Immunoadsorption

Affiliations
Case Reports

Successful Emergency Management of a Dog with Ventilator-Dependent Acquired Myasthenia Gravis with Immunoadsorption

Florian Sänger et al. Animals (Basel). .

Abstract

A one-year-old, female intact Samoyed, 12.5 kg, was presented with coughing for 2 weeks, progressive appendicular and axial muscle weakness, megaesophagus and labored breathing for 5 days. There was no improvement with standard treatment. Acquired myasthenia gravis was suspected and the dog was referred with increasing dyspnea. At presentation, the dog showed a severely reduced general condition, was non-ambulatory and showed abdominal and severely labored breathing. A marked hypercapnia (PvCO2 = 90.1 mmHg) was present in venous blood gas analysis. The serum anti-acetylcholine receptor antibody test was consistent with acquired myasthenia gravis (2.1 nmol/L). The dog was anesthetized with propofol and mechanically ventilated with a Hamilton C1 ventilator. Immunoadsorption was performed with the COM.TEC® and ADAsorb® platforms and a LIGASORB® adsorber to eliminate anti-acetylcholine receptor antibodies. Local anticoagulation was performed with citrate. Treatment time for immunoadsorption was 1.5 h with a blood flow of 50 mL/min. A total plasma volume of 1.2 L was processed. Further medical treatment included intravenous fluid therapy, maropitant, esomeprazole, antibiotic therapy for aspiration pneumonia and neostigmine 0.04 mg/kg intramuscularly every 6 h for treatment of acquired myasthenia gravis. Mechanical ventilation was stopped after 12 h. A percutaneous gastric feeding tube was inserted under endoscopic control on day 2 for further medical treatment and nutrition. A second treatment with immunoadsorption was performed on day 3. Again, a total plasma volume of 1.2 L was processed. Immediately after this procedure, the dog regained muscle strength and was able to stand and to walk. After 6 days, the dog was discharged from the hospital. This is the first report of immunoadsorption for emergency management of a dog with acute-fulminant acquired myasthenia gravis. Immunoadsorption may be an additional option for emergency treatment in dogs with severe signs of acquired myasthenia gravis.

Keywords: acute fulminating myasthenia gravis; anti-acetylcholine receptor antibodies; generalized lower motor neuron; immunoadsorption; mechanical ventilation; megaesophagus.

PubMed Disclaimer

Conflict of interest statement

The authors declare that no conflict of interest could be perceived as prejudicing the impartiality of the research reported.

Figures

Figure 1
Figure 1
Thoracic radiograph of the dog with acute fulminating acquired myasthenia gravis during initial diagnostic workup. A generalized megaesophagus can be seen.
Figure 2
Figure 2
Treatment setup with immunoadsorption and mechanical ventilation for the dog with acquired myasthenia gravis.
Figure 3
Figure 3
Results of anti-acetylcholine receptor antibodies in a dog with acute fulminating acquired myasthenia gravis treated with immunoadsorption (IA), analyzed with radioimmunoassay, before and after IA. The red line marks the upper reference range.

Similar articles

Cited by

References

    1. Shelton G.D. Acquired myasthenia gravis: What we have learned from experimental and spontaneous animal models. Vet. Immunol. Immunopathol. 1999;69:239–249. doi: 10.1016/S0165-2427(99)00058-6. - DOI - PubMed
    1. Shelton G.D. Myasthenia gravis and congenital myasthenic syndromes in dogs and cats: A history and mini-review. Neuromuscul. Disord. 2016;26:331–334. doi: 10.1016/j.nmd.2016.03.002. - DOI - PubMed
    1. Forgash J.T., Chang Y., Mittelman N.S., Petesch S., Benedicenti L., Galban E., Hammond J.J., Glass E.N., Barker J.R., Shelton G.D., et al. Clinical features and outcome of acquired myasthenia gravis in 94 dogs. J. Vet. Intern. Med. 2021;35:2315–2326. doi: 10.1111/jvim.16223. - DOI - PMC - PubMed
    1. Huijbers M.G., Marx A., Plomp J.J., Le Panse R., Phillips W.D. Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21:163–175. doi: 10.1016/S1474-4422(21)00357-4. - DOI - PubMed
    1. Spurlock N., Prittie J. Use of Human Intravenous Immunoglobulin in Veterinary Clinical Practice. Vet. Clin. Small Anim. Pract. 2020;50:1371–1383. doi: 10.1016/j.cvsm.2020.07.015. - DOI - PubMed

Publication types

LinkOut - more resources